Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Dreyling

Showing results (61-70 of 336) with videos related to

Pageof 34
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2014
New paradigms in mantle cell lymphoma: is it time to risk-stratify treatment based on the proliferative signature?Martin Dreyling, Simone Ferrero, Niklas Vogt, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 7, 2026
Modern Management of Mantle Cell LymphomaTobias Tix, Anita Kumar, Toby A Eyre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2020
High-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and ManagementPreetesh Jain, Martin Dreyling, John F Seymour, et al.
Critical Reviews in Oncology/Hematology|June 11, 2011
Mantle cell lymphomaSergio Cortelazzo, Maurilio Ponzoni, Andrés J M Ferreri, et al.
BMC Cancer|June 27, 2013
A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma - the STORM trialMathias Witzens-Harig, Marie Luise Memmer, Martin Dreyling, et al.
Leukemia & Lymphoma|June 19, 2018
Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trialsRishu Agarwal, Mark A Dawson, Martin Dreyling, et al.
Blood|August 30, 2011
Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphomaRobert Griffiths, Joseph Mikhael, Michelle Gleeson, et al.
Seminars in Hematology|July 26, 2011
Treatment of younger patients with mantle cell lymphomaStéphanie Harel, Richard Delarue, Vincent Ribrag, et al.
Critical Reviews in Oncology/Hematology|August 3, 2020
Mantle cell lymphomaSergio Cortelazzo, Maurilio Ponzoni, Andrés J M Ferreri, et al.
Haematologica|January 26, 2006
Current status and perspective of antibody therapy in follicular lymphomaChristian Buske, Oliver Weigert, Martin Dreyling, et al.
Pageof 34

Showing results (61-70 of 336) with videos related to

Sort By:
Pageof 34
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2014
New paradigms in mantle cell lymphoma: is it time to risk-stratify treatment based on the proliferative signature?Martin Dreyling, Simone Ferrero, Niklas Vogt, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 7, 2026
Modern Management of Mantle Cell LymphomaTobias Tix, Anita Kumar, Toby A Eyre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2020
High-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and ManagementPreetesh Jain, Martin Dreyling, John F Seymour, et al.
Critical Reviews in Oncology/Hematology|June 11, 2011
Mantle cell lymphomaSergio Cortelazzo, Maurilio Ponzoni, Andrés J M Ferreri, et al.
BMC Cancer|June 27, 2013
A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma - the STORM trialMathias Witzens-Harig, Marie Luise Memmer, Martin Dreyling, et al.
Leukemia & Lymphoma|June 19, 2018
Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trialsRishu Agarwal, Mark A Dawson, Martin Dreyling, et al.
Blood|August 30, 2011
Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphomaRobert Griffiths, Joseph Mikhael, Michelle Gleeson, et al.
Seminars in Hematology|July 26, 2011
Treatment of younger patients with mantle cell lymphomaStéphanie Harel, Richard Delarue, Vincent Ribrag, et al.
Critical Reviews in Oncology/Hematology|August 3, 2020
Mantle cell lymphomaSergio Cortelazzo, Maurilio Ponzoni, Andrés J M Ferreri, et al.
Haematologica|January 26, 2006
Current status and perspective of antibody therapy in follicular lymphomaChristian Buske, Oliver Weigert, Martin Dreyling, et al.
Pageof 34